vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and CATHAY GENERAL BANCORP (CATY). Click either name above to swap in a different company.
CATHAY GENERAL BANCORP is the larger business by last-quarter revenue ($222.8M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs 13.3%, a 640.1% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs -1.8%). CATHAY GENERAL BANCORP produced more free cash flow last quarter ($363.7M vs $24.6M). Over the past eight quarters, CATHAY GENERAL BANCORP's revenue compounded faster (12.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
AMPH vs CATY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $222.8M |
| Net Profit | $24.4M | $90.5M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 50.9% |
| Net Margin | 13.3% | 653.4% |
| Revenue YoY | -1.8% | 19.5% |
| Net Profit YoY | -35.7% | 12.9% |
| EPS (diluted) | $0.51 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $222.8M | ||
| Q3 25 | $191.8M | $210.6M | ||
| Q2 25 | $174.4M | $196.6M | ||
| Q1 25 | $170.5M | $187.8M | ||
| Q4 24 | $186.5M | $186.5M | ||
| Q3 24 | $191.2M | $189.5M | ||
| Q2 24 | $182.4M | $178.5M | ||
| Q1 24 | $171.8M | $175.2M |
| Q4 25 | $24.4M | $90.5M | ||
| Q3 25 | $17.4M | $77.7M | ||
| Q2 25 | $31.0M | $77.5M | ||
| Q1 25 | $25.3M | $69.5M | ||
| Q4 24 | $38.0M | $80.2M | ||
| Q3 24 | $40.4M | $67.5M | ||
| Q2 24 | $37.9M | $66.8M | ||
| Q1 24 | $43.2M | $71.4M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 50.9% | ||
| Q3 25 | 13.2% | 44.5% | ||
| Q2 25 | 24.2% | 49.0% | ||
| Q1 25 | 21.9% | 46.1% | ||
| Q4 24 | 24.2% | 46.5% | ||
| Q3 24 | 29.8% | 41.2% | ||
| Q2 24 | 30.3% | 40.7% | ||
| Q1 24 | 27.9% | 45.7% |
| Q4 25 | 13.3% | 653.4% | ||
| Q3 25 | 9.0% | 36.9% | ||
| Q2 25 | 17.8% | 39.4% | ||
| Q1 25 | 14.8% | 37.0% | ||
| Q4 24 | 20.4% | 587.9% | ||
| Q3 24 | 21.1% | 35.6% | ||
| Q2 24 | 20.8% | 37.4% | ||
| Q1 24 | 25.1% | 40.8% |
| Q4 25 | $0.51 | $1.33 | ||
| Q3 25 | $0.37 | $1.13 | ||
| Q2 25 | $0.64 | $1.10 | ||
| Q1 25 | $0.51 | $0.98 | ||
| Q4 24 | $0.74 | $1.11 | ||
| Q3 24 | $0.78 | $0.94 | ||
| Q2 24 | $0.73 | $0.92 | ||
| Q1 24 | $0.81 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $119.1M |
| Stockholders' EquityBook value | $788.8M | $2.9B |
| Total Assets | $1.6B | $24.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $119.1M | ||
| Q3 25 | $608.6M | $119.1M | ||
| Q2 25 | $607.7M | $119.1M | ||
| Q1 25 | $603.9M | $119.1M | ||
| Q4 24 | $601.6M | $119.1M | ||
| Q3 24 | $596.4M | $119.1M | ||
| Q2 24 | $586.9M | $119.1M | ||
| Q1 24 | $594.0M | $119.1M |
| Q4 25 | $788.8M | $2.9B | ||
| Q3 25 | $776.7M | $2.9B | ||
| Q2 25 | $757.5M | $2.9B | ||
| Q1 25 | $751.3M | $2.9B | ||
| Q4 24 | $732.3M | $2.8B | ||
| Q3 24 | $727.7M | $2.8B | ||
| Q2 24 | $713.3M | $2.8B | ||
| Q1 24 | $672.4M | $2.8B |
| Q4 25 | $1.6B | $24.2B | ||
| Q3 25 | $1.7B | $24.1B | ||
| Q2 25 | $1.6B | $23.7B | ||
| Q1 25 | $1.6B | $23.2B | ||
| Q4 24 | $1.6B | $23.1B | ||
| Q3 24 | $1.5B | $23.3B | ||
| Q2 24 | $1.5B | $23.2B | ||
| Q1 24 | $1.6B | $23.4B |
| Q4 25 | 0.77× | 0.04× | ||
| Q3 25 | 0.78× | 0.04× | ||
| Q2 25 | 0.80× | 0.04× | ||
| Q1 25 | 0.80× | 0.04× | ||
| Q4 24 | 0.82× | 0.04× | ||
| Q3 24 | 0.82× | 0.04× | ||
| Q2 24 | 0.82× | 0.04× | ||
| Q1 24 | 0.88× | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $368.6M |
| Free Cash FlowOCF − Capex | $24.6M | $363.7M |
| FCF MarginFCF / Revenue | 13.4% | 163.2% |
| Capex IntensityCapex / Revenue | 4.5% | 2.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 4.07× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $672.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $368.6M | ||
| Q3 25 | $52.6M | $150.6M | ||
| Q2 25 | $35.6M | $64.0M | ||
| Q1 25 | $35.1M | $99.0M | ||
| Q4 24 | $29.0M | $329.2M | ||
| Q3 24 | $60.0M | $81.2M | ||
| Q2 24 | $69.1M | $72.9M | ||
| Q1 24 | $55.3M | $88.2M |
| Q4 25 | $24.6M | $363.7M | ||
| Q3 25 | $47.2M | $150.1M | ||
| Q2 25 | $25.0M | $62.7M | ||
| Q1 25 | $24.4M | $96.3M | ||
| Q4 24 | $16.6M | $325.5M | ||
| Q3 24 | $46.2M | $80.0M | ||
| Q2 24 | $63.1M | $72.4M | ||
| Q1 24 | $46.5M | $87.3M |
| Q4 25 | 13.4% | 163.2% | ||
| Q3 25 | 24.6% | 71.3% | ||
| Q2 25 | 14.3% | 31.9% | ||
| Q1 25 | 14.3% | 51.2% | ||
| Q4 24 | 8.9% | 174.6% | ||
| Q3 24 | 24.1% | 42.2% | ||
| Q2 24 | 34.6% | 40.5% | ||
| Q1 24 | 27.1% | 49.8% |
| Q4 25 | 4.5% | 2.2% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 1.4% | ||
| Q4 24 | 6.7% | 1.9% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | 0.5% |
| Q4 25 | 1.35× | 4.07× | ||
| Q3 25 | 3.03× | 1.94× | ||
| Q2 25 | 1.15× | 0.83× | ||
| Q1 25 | 1.39× | 1.42× | ||
| Q4 24 | 0.76× | 4.10× | ||
| Q3 24 | 1.48× | 1.20× | ||
| Q2 24 | 1.82× | 1.09× | ||
| Q1 24 | 1.28× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CATY
Segment breakdown not available.
